• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.

作者信息

Mittal Saurabh

机构信息

Department of Dermatology, NMC Royal Hospital, Abu Dhabi, UAE.

出版信息

Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):119-121. doi: 10.4103/ijdvl.IJDVL_671_19.

DOI:10.4103/ijdvl.IJDVL_671_19
PMID:33037161
Abstract
摘要

相似文献

1
Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.司库奇尤单抗继发治疗失败的银屑病患者对依奇珠单抗的反应。
Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):119-121. doi: 10.4103/ijdvl.IJDVL_671_19.
2
The successful treatment with ixekizumab in a multi-failure psoriasis patient.司库奇尤单抗成功治疗一名多系统功能衰竭的银屑病患者。
Dermatol Online J. 2018 Sep 10;24(9):13030/qt2qn1p4bz.
3
Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.司库奇尤单抗治疗失败后接受依奇珠单抗治疗的22例银屑病患者的长期随访
Dermatol Online J. 2020 Jan 15;26(1):13030/qt235408bf.
4
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
5
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.在英国，以司库奇尤单抗为对照，优时比单抗序贯生物治疗作为中重度银屑病一线治疗的成本效益分析
J Med Econ. 2018 Aug;21(8):810-820. doi: 10.1080/13696998.2018.1474747. Epub 2018 Jun 6.
6
IL-17 inhibitors for psoriasis.用于治疗银屑病的白细胞介素-17抑制剂
Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.
7
Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.司库奇尤单抗耐药或反应不完全患者中依奇珠单抗的疗效。
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):e338-e341. doi: 10.1111/jdv.15630. Epub 2019 Apr 29.
8
Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis.体重对司库奇尤单抗治疗中度至重度斑块状银屑病的风险效益及给药方案推荐的影响
Clin Pharmacol Ther. 2019 Jul;106(1):78-80. doi: 10.1002/cpt.1478. Epub 2019 Jun 12.
9
First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.一名银屑病患者在从司库奇尤单抗转换为布罗达单抗治疗时首次出现坏疽性脓皮病、掌跖脓疱病和骶髂关节炎。
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e406-e407. doi: 10.1111/jdv.15714. Epub 2019 Jun 13.
10
The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.白细胞介素-17在银屑病发病机制中的作用及斑块状银屑病白细胞介素-17抑制剂治疗进展
J Cutan Med Surg. 2016 Nov;20(6):509-516. doi: 10.1177/1203475416651605. Epub 2016 May 20.

本文引用的文献

1
Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.司库奇尤单抗治疗失败的慢性红皮病型银屑病病史患者使用依奇珠单抗的临床经验：病例系列
Br J Dermatol. 2019 Nov;181(5):1106-1107. doi: 10.1111/bjd.18174. Epub 2019 Aug 20.
2
IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.白细胞介素 17A 抑制剂转换 - 司库奇尤单抗治疗失败后使用依奇珠单抗的疗效。一项单中心经验。
Acta Derm Venereol. 2019 Jul 1;99(9):769-773. doi: 10.2340/00015555-3200.
3
Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.
白细胞介素-17 改变了许多参与银屑病发生、全身炎症和相关合并症的细胞类型的生物学特性。
Exp Dermatol. 2018 Feb;27(2):115-123. doi: 10.1111/exd.13467. Epub 2017 Dec 29.
4
Psoriasis and comorbid diseases: Epidemiology.银屑病及其合并症：流行病学
J Am Acad Dermatol. 2017 Mar;76(3):377-390. doi: 10.1016/j.jaad.2016.07.064.